Determining the benefit of levodopa/carbidopa/entacapone (Stalevo®) on the pharmacokinetic profile of levodopa:: a randomized, crossover, multicentre study in patients with Parkinson's disease

被引：0

作者：

Marttila, R. ^{[1
]}

Kaasinen, V. ^{[1
]}

Hartikainen, P. ^{[2
]}

Lyytinen, J. ^{[3
]}

Kaakkola, S. ^{[3
]}

Hanninen, J. ^{[4
,5
]}

Korpela, K. ^{[4
,5
]}

Laapas, K. ^{[4
,5
]}

Kuoppamaki, M. ^{[1
,4
,5
]}

Ellmen, J. ^{[4
,5
]}

机构：

[1] Turku Univ Hosp, Dept Neurol, FIN-20520 Turku, Finland

[2] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland

[3] Helsinki Univ Hosp, Dept Neurol, Helsinki, Finland

[4] Orion Phama, Turku, Finland

[5] Orion Pharma, Espoo, Finland

来源：

EUROPEAN JOURNAL OF NEUROLOGY | 2008年 / 15卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：115 / 115

页数：1

共 50 条

[1] Determining the benefit of levodopa/carbidopa/entacapone (Stalevo®) on the pharmacokinetic profile of levodopa:: a randomized, crossover, multicentre study in patients with Parkinson's disease
Kaakola, S.
Ellmen, J.
Marttila, R.
Kaasinen, V.
Hartikainen, P.
Lyytinen, J.
Hanninen, J.
Korpela, K.
Kuoppamaki, M.
PARKINSONISM & RELATED DISORDERS, 2007, 13 : S100 - S100
[2] Determining the benefit of levodopa/carbidopa/entacapone (Stalevo®) on the pharmacokinetic profile of levodopa:: A randomized, crossover, multicenter study in patients with Parkinson's disease
Marttila, R.
Kaasinen, V.
Hartikainen, P.
Lyytinen, J.
Kaakkola, S.
Haenninen, J.
Korpela, K.
Laapas, K.
Kuoppamaeki, M.
Ellmen, J.
MOVEMENT DISORDERS, 2008, 23 (01) : S213 - S213
[3] Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (Stalevo) in Parkinson disease patients
Lyons, KE
Pahwa, R
CLINICAL NEUROPHARMACOLOGY, 2006, 29 (02) : 73 - 76
[4] Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study
Senek, Marina
Nielsen, Elisabet I.
Nyholm, Dag
MOVEMENT DISORDERS, 2017, 32 (02) : 283 - 286
[5] Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease
Delea, Thomas E.
Thomas, Simu K.
Hagiwara, May
Mancione, L.
CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (07) : 1543 - 1552
[6] Levodopa/carbidopa/entacapone in Parkinson's disease
Seeberger, Lauren C.
Hauser, Robert A.
EXPERT REVIEW OF NEUROTHERAPEUTICS, 2009, 9 (07) : 929 - 940
[7] Stalevo (levodopa/carbidopa/entacapone) provides improved symptom control in fluctuating Parkinson's disease patients comparable to levodopa/DDCI given in combination with entacapone
Oertel, W
MOVEMENT DISORDERS, 2004, 19 : S258 - S258
[8] Improved adherence to levodopa/carbidopa/entacapone (Stalevo®) or levodopa/carbidopa and entacapone as separate tablets reduces medical care utilization and costs among Parkinson's disease patients
Delea, T.
Thomas, S.
Hagiwara, M.
Stacy, M.
PARKINSONISM & RELATED DISORDERS, 2007, 13 : S100 - S101
[9] Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease - A randomized, crossover infusion study
Senek, M.
Nyholm, D.
MOVEMENT DISORDERS, 2016, 31 : S621 - S622
[10] A randomized, double-blind study to compare the effect on quality of life of levodopa/carbidopa/entacapone (Stalevo®) with levodopa/carbidopa in patients with Parkinson's disease with no or minimal, nondisabling motor fluctuations
Fung, V. S.
MOVEMENT DISORDERS, 2006, 21 : S446 - S446

← 1 2 3 4 5 →